Hong Kong Regen Medtech Limited (HKRM) is a stem cell biotechnology company dedicated to developing stem cell therapies for intractable diseases. Through harnessing the therapeutic potential of stem cells, HKRM is developing new medicine targeting degenerative and immunological diseases. HKRM engineers stem cell manipulation and differentiation platform mimicking native developmental niches to generate high-quality cell therapy products.
On August 1 2021, the Department of Health in Hong Kong implemented all provisions of the Pharmacy and Poisons (Amendment) Ordinance 2020 (the Amendment Ordinance) to introduce a regulatory framework for Advanced Therapy Products (ATPs).
In compliance with the Amendment Ordinance, Hong Kong Regen Medtech aspires to be the first private company with a PICS/GMP ATP cell processing facility in Asia and provides the highest quality ATPs to the patients.
To establish state-of-the-art stem cell therapies in Asia, complying with the highest standard of the industry
To accomplish one’s desire for healthy longevity through stem cell therapies